In Depth 21 Nov 2024 Huntington’s disease: a therapeutic field on a bumpy ride …in 2022 upon demanding more dosage data. Prilenia’s Huntington’s candidate pridopidine accepted for EMA review Meanwhile, Dutch biotech Prilenia Therapeutics’ Huntington’s candidate is en route to approval. Two weeks ago,… November 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 License granted to EnteroBiotix for manufacture of microbiome product candidates Microbiome therapeutics company, EnteroBiotix Limited has been granted a manufacturer’s license for a GMP manufacturing facility for Investigational Medicinal Products (IMP) to make microbiome product candidates for clinical trials. It… October 11, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 FDA fast tracks Immutep non-small cell lung cancer candidate …first line non-small cell lung cancer (NSCLC). Efti is the company’s first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage both the innate and adaptive… October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 29 Nov 2023 Redefining drug development: the trailblazing evolution of the pharmaceutical industry …after drug candidates are rigorously optimized at the preclinical stage. However, nine out of ten drug candidates would fail during phase 1, 2, 3 clinical trials and drug approval. It… November 29, 2023 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16,… October 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic Ipsen and Marengo Therapeutics, Inc. have announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. Ipsen also announced it is exercising its option… August 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2023 The promise of immunotherapy for autoimmune diseases …drug, 1104. The candidate binds to monocytes – which mature into dendritic cells – and modifies the regulatory signal that causes them to activate regulatory dendritic cells, regulatory T cells… June 27, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to… October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Remedium raises more funds for osteoarthritis gene therapy candidate …candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a placebo controlled,… August 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 NodThera announces positive inflammatory disease data NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a… June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Enterome and Nestlé Health Science to work on food allergies and inflammatory bowel disease …targeting food allergies and inflammatory bowel disease (IBD). The collaboration aims to develop and commercialize Enterome’s lead EndoMimics pipeline candidate EB1010. EB1010 is a local inducer of IL-10 designed to… July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Feb 2024 10 gene therapy companies you should know about …in vivo approaches to develop their candidates. Its lead candidate is an ex vivo therapy called reni-cell, which is intended to treat sickle cell disease and beta-thalassemia. Reni-cel is currently… February 22, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email